North America Virus-like Particles Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Hepatitis, Cancer/HPV, and Gaucher disease), Source (Yeast, Insect Cell, Plant, and Others), and Application (Vaccines and Therapeutics)
Market Introduction
The North America virus-like particles market analysis is based on three major countries: the US, Canada, and Mexico. Among North America provinces, US holds the largest size of the VLP's market due to reported viral infections, for example, variant influenza viruses. According to the Centers for Disease Control and Prevention (CDC), the majority of the conditions of variant viruses have mainly occurred in children aged 18 years or younger with the onset of illness, according to the report by the Centers for Disease Control and Prevention (CDC). Additionally, consistent R&D activities to manufacture live attenuated vaccines by the biopharmaceutical company positively impact the market growth.
In the North American provinces, the US was the most affected country due to COVID-19. This was due to the US showing an uneven response during the onset of COVID-19 coupled with insufficiencies in testing resources. To overcome the transmission rate of COVID-19, the development of the vaccine was on edge for all biopharmaceutical companies with a high focus on recombinant COVID-19 vaccines. As recombinant vaccines include recombinant spike protein vaccines, recombinant receptor-binding domain vaccines, and virus-like particles, it has gained high importance. Also, the development of more effective and targeted forms of VLP by modification of the surface of the particles in a fashion that they can be introduced into specific cells or tissues is likely to grow in the forthcoming years. Recent advances in the production of VLP's involve the different types of expression systems for the development as well as application of vaccines in the prevention of infectious diseases. In the North American region, countries where COVID-19 vaccines are currently being developed, including the US, Canada, and Cuba. Among these countries, the US has eleven vaccines, while Canada and Cuba possess three vaccines. Additionally, there are six protein subunit vaccines comprising of VLPs, five vector vaccines, and five nucleic acid vaccines. But the manufacturing of virus-like particles still remains challenging in terms of design, purification, and storage. Challenges are majorly associated with the bioprocessing technique that deals with respiratory issues. However, with strong advancement in technology it ultimately develops a series of novel, stable, and efficient VLP based vaccine candidates in the near future.
Get more information on this report : 
Market Overview and Dynamics
The virus-like particles market in North America is expected to grow from US$ 1,928.37 million in 2021 to US$ 3,312.49 million by 2028; it is estimated to grow at a CAGR of 8.0% from 2021 to 2028. Various players in the healthcare market and research organizations are actively involved in product innovations and developments. The use of virus-like particles is an emerging approach used in the biopharmaceuticals industry. As virus-like particles lack the viral content, they are easier to handle than the actual viral components. The VLPs can be used for aiding drug delivery, imaging, immunotherapy, and theragnostic. For instance, as per a study published in the NCBI in June 2020, VLP can be used in the form of nanoparticles in applications such as photothermal therapy, PET and CT imaging, MRI contrast agent carriers, optical imaging, inflammatory and autoimmune disease vaccines, cancer immunotherapy, and small molecule drug delivery (in cancer therapy). Thus, such potential applications of VLPs are expected to provide growth opportunities to market players during the forecast period.
Key Market Segments
In terms of product type, the hepatitis segment accounted for the largest share of the North America virus-like particles market in 2021. In terms of source, the yeast segment accounted for the largest share of the North America virus-like particles market in 2021. In term of application, vaccines segment held a larger market share of the virus-like particles market in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the virus-like particles market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Merck & Co., Inc.; GlaxoSmithKline plc.; Pfizer Inc.; Sanofi; Serum Institute of India Pvt. Ltd.; BHARAT BIOTECH; LG Chem; VBI Vaccines Inc.; and Dynavax Technologies among others.
Reasons to buy report
- To understand the North America virus-like particles market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America virus-like particles market
- Efficiently plan M&A and partnership deals in North America virus-like particles market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America virus-like particles market
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
North America Virus-like Particles Market Segmentation
North America Virus-like Particles Market – By Product type
- Hepatitis
- Cancer/HPV
- Gaucher Disease
North America Virus-like Particles Market – By Source
- Yeast
- Insect Cell
- Plant
- Others
North America Virus-like Particles Market – By Application
- Vaccines
- Therapeutics
North America Virus-like Particles Market – By Country
- US
- Canada
- Mexico
North America Virus-like Particles Market – Companies Mentioned
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
- Dynavax Technologies
Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Virus-like Particles Market – By Product Type
1.3.2 North America Virus-like Particles Market – By Source
1.3.3 North America Virus-like Particles Market – By Application
1.3.4 North America Virus-like Particles Market – By Country
2. North America Virus-like Particles Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Virus-like Particles Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. North America Virus-like Particles Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Infectious Viral Diseases
5.1.2 The Elevating Role of Virus-Like Particles in Therapeutic Developments and Studies
5.2 Market Restraints
5.2.1 Presence of Alternative Technologies for Viral Vaccine Production
5.3 Market Opportunities
5.3.1 Raising Potential Applications in Therapeutics and Diagnostics
5.4 Future Trends
5.4.1 Constant Demand for Innovative and Effective Products
5.5 Impact Analysis
6. North America Virus-like Particles Market Analysis
6.1 North America Virus-like Particles Market Revenue Forecast and Analysis
7. North America Virus-like Particles Market Analysis – by Product Type
7.1 Overview
7.2 North America Virus-like Particles Market, by Product Type, 2021 & 2028 (%)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
7.4 Cancer/ Human Papillomavirus (HPV)
7.4.1 Overview
7.4.2 Cancer/HPV: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
7.5 Gaucher Disease
7.5.1 Overview
7.5.2 Gaucher Disease: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8. North America Virus-like Particles Market Analysis – By Source
8.1 Overview
8.2 North America Virus-like Particles Market Share, by Source, 2021 & 2028 (%)
8.3 Yeast
8.3.1 Overview
8.3.2 Yeast: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.4 Plant
8.4.1 Overview
8.4.2 Plant: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.5 Insect Cell
8.5.1 Overview
8.5.2 Insect Cell: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
9. North America Virus-like Particles Market Analysis – By Application
9.1 Overview
9.2 North America Virus-like Particles Market Share, by Application, 2021 & 2028 (%)
9.3 Vaccines
9.3.1 Overview
9.3.2 Vaccine: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
9.4 Therapeutics
9.4.1 Overview
9.4.2 Therapeutics: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
10. North America Virus-like Particles Market – Country Analysis
10.1 Overview
10.1.1 North America: Virus-like Particles Market, by Country, 2021 & 2028 (%)
10.1.1.1 US: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 US: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 US: Virus-like Particles Market, by Product Type, 2019–2028 (US$ Million)
10.1.1.1.4 US: Virus-like Particles Market, by Source, 2019–2028 (US$ Million)
10.1.1.1.5 US: Virus-like Particles Market, by Application, 2019–2028 (US$ Million)
10.1.1.2 Canada: Virus-Like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Canada: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 Canada: Virus-like Particles Market, by Product Type, 2019–2028 (US$ Million)
10.1.1.2.4 Canada: Virus-like Particles Market, by Source, 2019–2028 (US$ Million)
10.1.1.2.5 Canada Virus-Like Particles Market, by Application, 2019–2028 (US$ Million)
10.1.1.3 Mexico: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Mexico: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 Mexico: Virus-like Particles Market, by Product Type, 2019–2028 (US$ Million)
10.1.1.3.4 Mexico: Virus-like Particles Market, by Source, 2019–2028 (US$ Million)
10.1.1.3.5 Mexico: Virus-like Particles Market, by Application, 2019–2028 (US$ Million)
11. Impact Of COVID-19 Pandemic on North America Virus-like Particles Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. North America Virus-like Particles Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Dynavax Technologies
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sanofi
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Serum Institute of India Pvt. Ltd.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 BHARAT BIOTECH
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 LG Chem
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 VBI Vaccines Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Virus-like Particles Market, Revenue and Forecast to 2028 (US$ Million)
Table 2. US Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. US Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 4. US Virus-like Particles Market Revenue and Forecasts to 2028, by Application (US$ Million)
Table 5. Canada: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. Canada Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 7. Canada Virus-Like Particles Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 8. Mexico: Virus-like Particles Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. Mexico Virus-like Particles Market, by Source– Revenue and Forecast to 2028 (US$ Million)
Table 10. Mexico Virus-like Particles Market Revenue and Forecasts to 2028, by Application (US$ Million)
Table 11. Organic Developments Done by Companies
Table 12. Inorganic Developments Done by Companies
Table 13. Glossary of Terms: Virus-like Particles Market
LIST OF FIGURES
Figure 1. North America Virus-like particles Market Segmentation
Figure 2. North America Virus-like particles Market Segmentation, By Country
Figure 3. North America Virus-like Particles Market Overview
Figure 4. Hepatitis Held the Largest Share of the Product Type Segment in North America Virus-like particles Market
Figure 5. The US to Show Significant Growth during Forecast Period
Figure 6. North America Virus-like Particles Market, Industry Landscape
Figure 7. North America PEST Analysis
Figure 8. North America Virus-like Particles Market: Impact Analysis of Drivers and Restraints
Figure 9. North America Virus-like Particles Market– Revenue Forecast and Analysis to 2028
Figure 10. North America Virus-like Particles Market, by Product Type, 2021 & 2028 (%)
Figure 11. Hepatitis: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 12. Cancer/HPV: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 13. Gaucher Disease: Virus-like Particles Market Revenue and Forecast to 2028 (US$ Million)
Figure 14. North America Virus-like Particles Market Share, by Source, 2021 & 2028 (%)
Figure 15. Yeast: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Plant: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Insect Cell: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Others: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. North America Virus-like Particles Market Share, by Application, 2021 & 2028 (%)
Figure 20. Vaccine: Virus-like Particles Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Therapeutics: Virus-like Particles Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. North America: Virus-like Particles Market, by Key Country – Revenue (2021) (US$ Million)
Figure 23. North America: Virus-like Particles Market, by Country, 2021 & 2028 (%)
Figure 24. US: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Canada: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Mexico: Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Impact of COVID-19 Pandemic in North American Country Markets
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
- Dynavax Technologies
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America virus-like particles market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America virus-like particles market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the virus-like particles market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution